Reply to: Key Considerations for the Lenvatinib-Pembrolizumab-Chemotherapy Regimen in Advanced Gastric Cancer: Insights From LEAP-015

J Clin Oncol. 2026 Feb;44(4):346. doi: 10.1200/JCO-25-02148. Epub 2025 Dec 11.
No abstract available